Article
A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients.
Cancer - 1 Jul 1991
Green-Gallo L A, Buivys D M, Fisher K L, Caporaso N, Slawson R G, Elias G, Didolkar M S, Ivusich W J, Resau J H
Abstract excerpt
The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control study. The subjects were characterized by their ability to metabolize debrisoquine after receiving a test dose of the drug followed by the collection of an 8-hour...
Topics
- Blood Pressure
- Case-Control Studies
- Clinical Protocols
- Debrisoquin
- Humans
- Lung Neoplasms
- Middle Aged
- Monitoring, Physiologic
- Patient Education as Topic
- Phenotype
- Risk Factors